Metabolism of the diuretic bumetanide in healthy subjects and patients with renal impairment

The pharmacokinetics and metabolism of orally administered bumetanide were studied in five healthy subjects and in five patients with renal insufficiency. Healthy subjects excreted 51% of the dose as unchanged drug in the urine, whilst the patients with renal insufficiency excreted only 11% of the d...

Full description

Saved in:
Bibliographic Details
Published inEuropean journal of clinical pharmacology Vol. 38; no. 6; p. 583
Main Authors Howlett, M R, Skellern, G G, Auld, W H, Murdoch, W R
Format Journal Article
LanguageEnglish
Published Germany 01.01.1990
Subjects
Aged
Bumetanide - metabolism
Bumetanide - pharmacokinetics
Bumetanide - urine
Diuretics - metabolism
Female
Furosemide - metabolism
Furosemide - pharmacokinetics
Furosemide - urine
Half-Life
Humans
Kidney Diseases - metabolism
Kidney Diseases - urine
Male
Middle Aged
Online AccessGet more information

Cover

More Information
Summary:The pharmacokinetics and metabolism of orally administered bumetanide were studied in five healthy subjects and in five patients with renal insufficiency. Healthy subjects excreted 51% of the dose as unchanged drug in the urine, whilst the patients with renal insufficiency excreted only 11% of the dose as bumetanide. Similarly the urinary excretion of the gamma-hydroxybutyl metabolite was reduced from 6% in healthy subjects to 2.3% in patients with renal impairment. In both groups of subjects the mean elimination half-life of the metabolite was greater than for bumetanide. The results indicate a possible accumulation of bumetanide and metabolite in patient with renal failure.
ISSN:0031-6970
DOI:10.1007/BF00278586